The prognostic value of TREM-1 was analyzed in breast cancer, non-small-cell lung cancer (NSCLC), papillary thyroid cancer (PTC), etc. The recent data indicated that TREM-1 might promote tumor development and metastasis by promoting the tumor immune microenvironment, and increased TREM-1 values could be a prognostic factor for cancer outcomes and may contribute to myeloid-mediated cancer progression and immune suppression, cancer recurrence, and poor survival. This evidence concerns the gene TREM1 and breast carcinoma.